Pre-procedural SGLT2 inhibitors use significantly reduces CIN incidence, mortality, MACE, and HF readmission in PCI-treated AMI patients, suggesting potential cardiorenal protective benefits. Here, SLC5A2 is linked to cervical squamous intraepithelial neoplasia.